Patents Assigned to LUDWIGS-MAXIMILIANS-UNIVERSITÄT MÜNCHEN
-
Publication number: 20240336681Abstract: The present invention relates to an anti-CD47 antibody or an antigen-binding fragment thereof, comprising variable heavy chain complementarity determining regions 1 to 3 (CDRH1, CDRH2, CDRH3) and variable light chain complementarity determining regions 1 to 3 (CDRL1, CDRL2, CDRL3). The anti-CD47 antibody or an antigen-binding fragment thereof is capable of blocking the interaction of CD47 with signal regulatory protein alpha (SIRPalpha). Further envisaged is an anti-CD47 antibody or antigen-binding fragment combined to a further functional component.Type: ApplicationFiled: July 8, 2022Publication date: October 10, 2024Applicant: Ludwig-Maximilians-Universität MünchenInventors: Karl-Peter HOPFNER, Marion SUBKLEWE, Alexandra SCHELE, Nadja FENN, Enrico PERINI, Markus EISELE, Elisabeth KREMMER, Heinrich FLASWINKEL, Heinrich LEONHARDT
-
Patent number: 12046866Abstract: A multiple frequency comb source apparatus (100) for simultaneously creating a first laser pulse sequence representing a first frequency comb (1) and at least one further laser pulse sequence representing at least one further frequency comb (2), wherein at least two of the first and at least one further pulse sequences have different repetition frequencies, comprises a laser resonator device (10) comprising multiple resonator mirrors including first end mirrors EM1,OC1 providing a first laser resonator (11), a laser gain medium (21, 22) being arranged in the laser resonator device (10), and a pump device (30) being arranged for pumping the laser gain medium (21), wherein the laser resonator device (10) is configured for creating the first and at least one further laser pulse sequences by pumping and passively mode-locking the laser gain medium (21), the resonator mirrors of the laser resonator device (10) include further end mirrors EM2, OC2 providing at least one further laser resonator (12), the first laserType: GrantFiled: March 25, 2019Date of Patent: July 23, 2024Assignees: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e. V., Ludwig-Maximilians-Universitaet MuenchenInventors: Oleg Pronin, Ferenc Krausz, Ka Fai Mak, Jonathan Brons, Maksim Iandulskii
-
Patent number: 11958880Abstract: The present invention provides means and methods for equipping a polypeptide of interest at its C-terminus with a versatile adaptor amino acid that allows the functionalization of the polypeptide of interest.Type: GrantFiled: June 29, 2022Date of Patent: April 16, 2024Assignees: LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN, FORSCHUNGSVERBUND BERLIN E.V.Inventors: Heinrich Leonhardt, Jonas Helma, Dominik Schumacher, Christian Hackenberger
-
Patent number: 11746124Abstract: Disclosed are novel conjugates and processes for the preparation thereof.Type: GrantFiled: August 30, 2021Date of Patent: September 5, 2023Assignees: FORSCHUNGSVERBUND BERLIN E.V., LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHENInventors: Christian Hackenberger, Marc André Kasper, Maria Glanz, Tom Sauer, Dominik Schumacher, Jonas Helma-Smets, Heinrich Leonhardt, Andreas Stengl
-
Patent number: 11723922Abstract: The present invention relates to CXCR6-transduced (a) T cell(s) such as (a) CD8+ T cell(s), (a) CD4+ T cell(s), (a) CD3+ T cell(s), (a) ?? T cell(s) or (a) natural killer (NK) T cell(s) for targeted tumor therapy, nucleic acid sequences, vectors capable of transducing such (a) T cell(s), (a) transduced T cell(s) carrying the nucleic acid sequences or vectors of the present invention, methods and kits comprising the nucleic acid sequences or vectors of the present invention. The invention also provides the use of said transduced T cell(s) in a method for the treatment of diseases characterized by CXCL16 overexpression as well as a pharmaceutical composition/medicament comprising (a) transduced T cell(s) expressing the CXCR6 for use in methods of treating diseases characterized by CXCL16 overexpression.Type: GrantFiled: October 14, 2016Date of Patent: August 15, 2023Assignee: LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHENInventors: Sebastian Kobold, Stefan Endres, Moritz Rapp, Simon Grassmann
-
Patent number: 11552442Abstract: A laser device (100), being configured for generating laser pulses by Ken lens based mode locking, comprises a laser resonator (10) with a plurality of resonator mirrors (11.1, 11.2, 11.Type: GrantFiled: January 23, 2019Date of Patent: January 10, 2023Assignees: MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V., LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHENInventors: Oleg Pronin, Ferenc Krausz, Sebastian Groebmeyer, Jonathan Brons
-
Patent number: 11530976Abstract: A particle analysis method and apparatus, including a spectrometry-based analysis of a fluid sample (1), comprises the steps of creating a sample light beam S and a probe light beam P with a light source device (10) and periodically varying a relative phase between the sample and probe light beams S, P with a phase modulator device (20), irradiating the fluid sample (1) with the sample light beam S, detecting the sample and probe light beams S, P with a detector device (40), and providing a spectral response of the at least one particle (3), wherein the light source device (10) comprises at least one broadband source, which has an emission spectrum covering a mid-infrared MIR frequency range, and the phase modulator device (20) varies the relative phase with a scanning period equal to or below the irradiation period of irradiating the at least one particle (3, 4).Type: GrantFiled: September 14, 2018Date of Patent: December 20, 2022Assignees: Max-Planck-Fesellschaft zur Foerderung der Wissenschaften e.V., Ludwig-Maximilians-Universitaet MuenchenInventors: Ferenc Krausz, Ioachim Pupeza, Mihaela Zigman Kohlmaier, Marinus Huber
-
Patent number: 11513076Abstract: The present invention relates to a method and a DNA nanostructure for detecting a target structure. In particular, the present invention relates to a DNA nanostructure, which ensures a preferably linear dependence on the number of marker molecules and the measurement signal regardless of the physical arrangement of a plurality of such DNA nanostructures by virtue of the skilled selection of the shape of the DNA nanostructure and the placement of the marker molecules attached to it. The invention additionally relates to the use of said DNA nanostructures and other nanoreporters, preferably in combination with adapters which bind specifically to target molecules, in a method for quantifying a plurality of target molecules, preferably in a simultaneous manner, using a multiplex method.Type: GrantFiled: June 14, 2017Date of Patent: November 29, 2022Assignee: LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHENInventors: Heinrich Grabmayr, Johannes Benedikt Woehrstein
-
Publication number: 20220332737Abstract: The present invention relates to novel hydrolytically stable carbon-cyclic 5-aza-2-deoxycytidine and carbocyclic 5-aza-cytidine compounds and pro-drugs thereof as hypomethylating agents.Type: ApplicationFiled: June 5, 2019Publication date: October 20, 2022Applicant: Ludwig-Maximilians-Universität MünchenInventor: Thomas CARELL
-
Publication number: 20220296718Abstract: The present invention relates to excipients for stabilizing active agents, in particular peptides, polypeptides, nucleic acids, viruses, virus-like particles, proton pump inhibitors and antibiotics. The excipient reduces aggregate and/or particle formation in preparations comprising said agents. The excipient is a diamide of a dicarboxylic acid comprising at least one N—H amido group, at least one unsubstituted or substituted N-hydroxyethylamido group and/or at least one unsubstituted N-hydroxymethylamido group. In particular, the excipient is N,N,N?,N?-tetrakis-(2-hydroxyethyl) adipinic acid amide.Type: ApplicationFiled: July 10, 2020Publication date: September 22, 2022Applicants: Ludwig-Maximilians-Universität München, Danmarks Tekniske Universitet (DTU)Inventors: Gerhard WINTER, Andreas TOSSTORFF, Günther PETERS
-
Publication number: 20220265782Abstract: The present invention relates to compositions comprising a therapeutic protein with enhanced stability, which comprise a piperazine- or morpholine-containing zwitterionic buffering substance, such as HEPES, in particular when used out of the common pH range. The compositions of the invention are particularly useful for topical administration The present invention further relates to the use of said compositions for treating bacterial infections, e.g. bacterial infections caused by Staphylococcus aureus such as methicillin-resistant Staphylococcus aureus (MRSA). The present invention further relates to the use of said compositions for preventing or eliminating nasal bacterial colonization or bacterial colonization of the skin.Type: ApplicationFiled: July 16, 2020Publication date: August 25, 2022Applicants: LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN, HYPHARM GMBHInventors: Gerhard WINTER, Simon EISELE, Sonja MOLINARO, Wolfgang MUTTER
-
Patent number: 11422094Abstract: The analysis of data from fluorescence microscopy is disclosed, more especially fluorescence fluctuation microscopy, being a correlation analysis of fluctuation of the fluorescence intensity enabling quantitative and dynamic information capture. In particular the analysis is described of characteristics such as concentrations, mobility, interactions, stoichiometry, etc. of mixtures of particular that are fluorescently labeled with differently colored fluorophores having different excitation/emission spectra using fluctuation microscopy.Type: GrantFiled: January 11, 2019Date of Patent: August 23, 2022Assignees: Universiteit Hasselt, Ludwig-Maximilians-Universität MünchenInventors: Jelle Hendrix, Nick Smisdom, Don Lamb, Waldemar Schrimpf
-
Patent number: 11401298Abstract: The present invention provides means and methods for equipping a polypeptide of interest at its C-terminus with a versatile adaptor amino acid that allows the functionalization of the polypeptide of interest.Type: GrantFiled: August 14, 2020Date of Patent: August 2, 2022Assignees: LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN, FORSCHUNGSVERBUND BERLIN E.V.Inventors: Heinrich Leonhardt, Jonas Helma, Dominik Schumacher, Christian Hackenberger
-
Patent number: 11229700Abstract: The present invention relates to a novel molecule comprising three binding sites with specificity for a tumor cell, for an effector cell and for a checkpoint molecule, respectively. Moreover, the present invention relates to a pharmaceutical composition comprising such a molecule and to uses of such a molecule.Type: GrantFiled: November 9, 2016Date of Patent: January 25, 2022Assignee: LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHENInventors: Karl-Peter Hopfner, Marion Subklewe, Nadine Magauer, Nadja Fenn
-
Patent number: 11199496Abstract: A method of measuring a polarization response of a sample (1), in particular a biological sample, comprises the steps of generating a sequence of excitation waves (2), irradiating the sample (1) with the sequence of excitation waves (2), including an interaction of the excitation waves (2) with the sample (1), so that a sequence of sample waves (3) is generated each including a superposition of a sample main pulse and a sample global molecular fingerprint (GMF) wave (EGMF(sample)(t)), irradiating a reference sample (1A) with the sequence of excitation waves (2), including an interaction of the excitation waves (2) with the reference sample (1A), so that a sequence of reference waves (3A) is generated each including a superposition of a reference main pulse and a reference GMF wave (EGMF(ref)(t)), optically separating a difference of the sample waves (3) and reference waves (3A) from GMF wave contributions which are common to both of the sample waves (3) and reference waves (3A) in space and/or time, and detecType: GrantFiled: March 21, 2017Date of Patent: December 14, 2021Assignees: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V., Ludwig-Maximilians-Universitaet MuenchenInventors: Ferenc Krausz, Hanieh Fattahi, Marinus Huber, Joachim Pupeza, Mihaela Zigman Kohlmaier
-
Patent number: 11180518Abstract: The present invention relates to a compound represented by the formula (E) which is useful for treating or preventing melanoma.Type: GrantFiled: May 11, 2018Date of Patent: November 23, 2021Assignees: MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V., LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHENInventors: Dorothea Becker, Thomas M. Jovin, Christian Griesinger, Andrei Leonov, Sergey Ryazanov, Armin Giese, Tiago F. Outeiro, Diana F. Lazaro, Michael P. Schön, Margarete Schön
-
Patent number: 11161873Abstract: Disclosed are novel conjugates and processes for the preparation thereof. A process tor the preparation of alkene- or alkyne-phosphonamidates comprises the steps of (I) reacting a compound of formula (III), with an azide of formula (IV), to prepare a compound of formula (V), reacting a compound of formula (V) with a thiol-containing molecule of formula (VI), resulting in a compound of formula (VII).Type: GrantFiled: September 1, 2017Date of Patent: November 2, 2021Assignees: FORSCHUNGSVERBUND BERLIN E.V., LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHENInventors: Christian Hackenberger, Marc André Kasper, Maria Glanz, Tom Sauer, Dominik Schumacher, Jonas Helma-Smets, Heinrich Leonhardt, Andreas Stengl
-
Publication number: 20210246189Abstract: The present invention relates to a peptide comprising a reversible affinity tag (A); and a functionalization tag (F), wherein the peptide is linked to a target of interest (T). The peptide is useful as a versatile protein tag. The invention further provides structures comprising the peptide, nucleic acids, vectors, and host cells. Further, the invention provides methods of producing or using the peptide.Type: ApplicationFiled: August 30, 2019Publication date: August 12, 2021Applicants: TECHNISCHE UNIVERSITAET MUENCHEN, LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHENInventors: Dirk BUSCH, Manuel EFFENBERGER, Heinrich LEONHARDT, Andreas STENGL
-
Patent number: 10941200Abstract: The present invention relates to a binding molecule having a binding site within the ectodomain of the triggering receptor expressed on myeloid cells 2 (TREM2), wherein the binding molecule inhibits TREM2 cleavage. Said binding molecule is particularly useful for treating and/or preventing a neurological disorder, such as a neurodegenerative disorder. Also encompassed by the present invention is a pharmaceutical composition for use in treating and/or preventing a neurological disorder, wherein the pharmaceutical composition comprises the binding molecule of the present invention. Neurodegenerative disorders that may be treated and/or prevented by using the binding molecule of the present invention include Alzheimer's disease (AD), Frontotemporal lobar degeneration (FTLD), FTLD-like syndrome, Parkinson's disease, Nasu-Hakola disease, Multiple sclerosis (MS), Huntington disease, immune-mediated neuropathies, or Amyotrophic lateral sclerosis (ALS).Type: GrantFiled: July 24, 2017Date of Patent: March 9, 2021Assignees: Deutsches Zentrum Für Neurodegenerative Erkrankungen EV, Ludwig-Maximilians-Universität MünchenInventors: Christian Haass, Gernot Kleinberger, Kai Schlepckow
-
Patent number: 10855049Abstract: A pulse laser apparatus (100) for creating laser pulses (1), in particular soliton laser pulses (1), based on Kerr lens mode locking of a circulating light field in an oscillator cavity (10), comprises at least two resonator mirrors (11, 12, . . .Type: GrantFiled: February 23, 2017Date of Patent: December 1, 2020Assignees: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V., Ludwig-Maximilians-Universitaet MuenchenInventors: Oleg Pronin, Ferenc Krausz, Jonathan Brons